These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 6771071)

  • 1. Kinetic measurement of the interaction of rheumatoid factor with IgG-coated latex particles and the influence of the first component of human complement.
    Hällgren R
    Clin Exp Immunol; 1980 Jan; 39(1):154-63. PubMed ID: 6771071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human serum inhibits the interaction between C1q or rheumatoid factor and IgG-coated latex particles. Reduction of these C1-dependent properties after complement activation in vitro and in vivo.
    Hällgren R
    Immunology; 1979 Nov; 38(3):529-37. PubMed ID: 118112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetics of the agglutination of IgG-coated latex particles by C1q: the influence of heat-labile serum components.
    Hällgren R; Stålenheim G; Venge P
    Scand J Immunol; 1979; 9(4):365-72. PubMed ID: 441683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduction of the complement activation capacity of soluble IgG aggregates and immune complexes by IgM-rheumatoid factor.
    Doekes G; Schouten J; Cats A; Daha MR
    Immunology; 1985 Jul; 55(3):555-64. PubMed ID: 4018839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complement fixation by rheumatoid factor.
    Tanimoto K; Cooper NR; Johnson JS; Vaughan JH
    J Clin Invest; 1975 Mar; 55(3):437-45. PubMed ID: 1078825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of circulating antigen-antibody complexes by their inhibitory effect on the agglutination of IgG-coated particles by rheumatioid factor of Clq.
    Lurhuma AZ; Cambiaso CL; Masson PL; Heremans JF
    Clin Exp Immunol; 1976 Aug; 25(2):212-26. PubMed ID: 954232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection of immune complexes in idiopathic thrombopenia].
    Bragiel I; Walewska I
    Acta Haematol Pol; 1980; 11(4):267-74. PubMed ID: 7293689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetic studies of the association of complement components and IgG-coated latex particles incubated in normal or complement-activated human serum.
    Hällgren R
    Clin Exp Immunol; 1981 Apr; 44(1):191-200. PubMed ID: 7261475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Possible mechanisms of the first step of the classical complement activation pathway: binding and activation of C1.
    Füst G; Medgyesi GA; Rajnavölgyi E; Csécsi-Nagy M; Czikora K; Gergely J
    Immunology; 1978 Dec; 35(6):873-84. PubMed ID: 104923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of rheumatoid factor on complement-mediated phagocytosis.
    McDuffie FC; Brumfield HW
    J Clin Invest; 1972 Dec; 51(12):3007-14. PubMed ID: 4640945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Quantitative laser-nephelometric detection of rheumatoid factor, using IgG coated latex particles (author's transl)].
    Husmann K; Lakomek HJ; Richter O; Jacobi E; Krüskemper HL
    J Clin Chem Clin Biochem; 1981 Nov; 19(11):1125-30. PubMed ID: 7310334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of complement fixation by rheumatoid factor using a haemolytic assay system.
    Taylor-Upsahl MM; Johnson PM; Mellbye OJ; Natvig JB
    Clin Exp Immunol; 1977 May; 28(2):204-11. PubMed ID: 872448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles of IgG, IgM rheumatoid factor, and their complexes in the induction of polymorphonuclear leukocyte chemotactic factor from complement.
    Wagner T; Abraham G; Baum J
    J Clin Invest; 1974 Jun; 53(6):1503-11. PubMed ID: 4133792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester.
    Ramsland PA; Movafagh BF; Reichlin M; Edmundson AB
    J Mol Recognit; 1999; 12(5):249-57. PubMed ID: 10777254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference of rheumatoid factor activity by aspartame, a dipeptide methyl ester.
    Ramsland PA; Movafagh BF; Reichlin M; Edmundson AB
    J Mol Recognit; 1999; 12(4):249-57. PubMed ID: 10440996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic studies of phagocytosis. III. The complement-dependent opsonic and anti-opsonic effects of normal and sle sera.
    Håkansson L; Hällgren R; Venge P
    Immunology; 1982 Sep; 47(1):91-9. PubMed ID: 6981589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The internal image of IgG in cross-reactive anti-idiotypic antibodies against human rheumatoid factors.
    Fong S; Gilbertson TA; Carson DA
    J Immunol; 1983 Aug; 131(2):719-24. PubMed ID: 6863929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complement mediated inhibition of immune precipitation in rheumatoid arthritis: studies on interaction of heat aggregated IgG with IgM rheumatoid factor.
    O'Sullivan MM; Amos N; Williams BD
    Ann Rheum Dis; 1988 Aug; 47(8):675-80. PubMed ID: 3261968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Studies on the mechanism of L-agglutination (author's transl)].
    Von Fragstein S; Wigand R
    Z Immunitatsforsch Immunobiol; 1976 Aug; 151(1):430-41. PubMed ID: 60841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. C1- inactivator: its efficiency as a regulator of classical complement pathway activation by soluble IgG aggregates.
    Doekes G; van Es LA; Daha MR
    Immunology; 1983 Jun; 49(2):215-22. PubMed ID: 6852866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.